For the No.1 clinical service provider
Presentation ( “”) ,
.
Presentation ‘ ’
. “” .
, ‘’, ‘’, ‘’, ‘’, ‘(E)’ .
“” , , “”
. , Presentation
, .
.
( )
,
.
Disclaimer
Investment Highlights Appendix
I N V E S T O R R E L A T I O N S 2 0 2 1
Prologue
2.
INVESTOR RELATIONS 202105
CRO
(CRO) Prologue1
2
6~8 77%
77%
Prologue2
CRO CRO R&D
: PhRMA Annual Membership Survey, 2020
21 3 4
R&D R&D
:
R&D 15.7% 58.6%
/
$82,956 M
Value Chain ADM Korea Prologue3
, Total
/
1 20~80 , , , ,
2 100~300 , / ,
3 500~5,000 2~3 ,
4 , ,
PMS Regulatory Post Marketing Surveillance, 4~6
Total
I N V E S T O R R E L A T I O N S 2 0 2 1
Chapter 01.
Business Overview
1.
4.
INVESTOR RELATIONS 202109
CRO ,
20192003 20132007 20172005 20152009 2011 20202004 20142008 20182006
20162010 2012
: 2003~2007 : 2008~2017 : 2018~
CRO
2003.10
2005.06
2006.12
PMDA(Japan)
/
SRD
R&G Pharma studies
(MFDS)
Business Overview2
CRO (PMS)
82% 18% /
CRO Business Overview3
’03 ’12’07 ’16’05 ’14’09 ’18’04 ’13’08 ’17’06 ’15’10 ’19’11
’20
()
()
Business Overview4
CRO
3 (3) ()
:
’03 ’12’07 ’16’05 ’14’09 ’18’04 ’13’08 ’17’06 ’15’10 ’19’11
’20
8
17
22
19
30
25
39
7
11
43
32
4 19%
11%
1 26%
2 21%
3 53%
I N V E S T O R R E L A T I O N S 2 0 2 1
Chapter 02.
Market Analysis
INVESTOR RELATIONS 202114
: EvaluatePharma, June 2020
2019 20162023 20182021 201720252020 20242022 2026 2019
: , , 2020, KoNECT
419
CRO Market Analysis2
CRO , CRO
: Frost&Sullivan, July 2020
2019 2015 20162023E 2019 2020E2021E 2017 20182020E 2022E 2024E
2021E
: KoNECT 2020.12, CAGR
CRO CRO
:
Market Analysis3
CRO
: K-CLIC, 2019
/
8
2
1
I N V E S T O R R E L A T I O N S 2 0 2 1
Chapter 03.
Investment Highlights
2.
3.
4.
6. VISION
Investment Highlights1
,
TOP 10 TOP
2020
131
Investment Highlights2
: K-IFRS , 2018 9 12 , 2018 12
2018 20182019 20192020 2020
131.2
Investment Highlights3
,
2017 20172018 20182019 20192020 2020
: :
222
102
304
201
, 3
4 ( ) 4 ( )
:
Investment Highlights5
, 147
2018
400%
100%
200%
300%
2019 2020
: , 2019 ‘M73. , ’
112.0
217.3
49.2
325.6
37.9
344.7
Global CRO Company
CRC Oncology
SMART RESEARCH
2015
2019 1 CRO
(35% )
10
3
2
1
I N V E S T O R R E L A T I O N S 2 0 2 1
Appendix
4,500,000 ( 100%)
2021 517()~18()
2021 525()~26()
6,718,250 30.77% 6
675,000 3.09% 1
135,000 0.62% 3
INVESTOR RELATIONS 202126
Appendix2
CRO 18 CRO
Company Profile
www.admkorea.co.kr
2018.05.14
DNA
2020 2019 2018
13,120 10,206 2,389
5,695 6,229 1,103
7,425 3,977 1,286
3,895 3,127 0
3,531 851 100
18,889 14,552 7,804
1,847 1,899 748
20,736 16,451 8,552
5,903 4,486 3,620
420 1,007 1,020
6,323 5,493 4,640
1,720 156 154
4,576 6,358 6
(1,014) (1,001) (689)
9,059 5,376 4,335
72 68 107
14,413 10,958 3,912
(: ) (: )
: K-IFRS , 2018 9 12 2018 2018 10~12 .
5 19, 7 711 (, )
Tel 02-730-1457 I Fax 02-722-0152 I
[email protected]
